• Dépistage, diagnostic, pronostic

  • Essais de technologies et de biomarqueurs dans un contexte clinique

  • Leucémie

The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia

Menée sur une cohorte de 255 patients atteints d'une leucémie lymphocytaire chronique, cette étude évalue l'association entre diverses délétions du chromosome 13q14 et le pronostic de la maladie

Purpose: To further our understanding of the biology and prognostic significance of various chromosomal 13q14 deletions in CLL. Experimental Design: We have analyzed data from SNP 6.0 arrays to define the anatomy of various 13q14 deletions in a cohort of 255 CLL patients and have correlated two subsets of 13q14 deletions (type I: exclusive of RB1 and type II: inclusive of RB1) with patient survival. Further, we have measured the expression of the 13q14-resident microRNAs by Q-PCR in 242 CLL patients and subsequently assessed their prognostic significance. We have sequenced all coding exons of RB1 in patients with monoallelic Rb1 deletion and have sequenced the 13q14-resident miR locus in all patients. Results: Large 13q14 (type II) deletions were detected in ~20% of all CLL patients and were associated with shortened survival. A strong association between 13q14 type II deletions and elevated genomic complexity, as measured through CLL-FISH or SNP 6.0 array profiling, was identified, suggesting that these lesions may contribute to CLL disease evolution through genomic destabilization. Sequence and copy number analysis of the RB1 gene identified a small CLL subset that is RB1 null. Finally, neither the expression levels of the 13q14-resident microRNAs nor the degree of 13q14 deletion, as measured through SNP 6.0 array-based copy number analysis, had significant prognostic importance. Conclusions: Our data suggest that the clinical course of CLL is accelerated in patients with large (type II) 13q14 deletions that span the RB1 gene, therefore justifying routine identification of 13q14 subtypes in CLL management.

Clinical Cancer Research , résumé, 2011

Voir le bulletin